The
nice people at Transfusion News sent their update today which focussed somewhat on sickle cell disease.
LentiGlobin Therapy for Sickle Cell Disease |
 January 4, 2022
Sickle
cell disease (SCD) is caused by a single point mutation in the β-globin
gene and affects around 100,000 people in the U.S. SCD can be cured in
14-20% of younger patients who have an HLA-matched donor, but allogeneic
hematopoietic stem-cell transplants also carry risk of
graft-versus-host disease, graft rejection, and even death. [Read More]
|
|
|
Cost-Effectiveness of Transfusions to Prevent Silent Cerebral Infarcts in Children with Sickle Cell Disease |
 December 29, 2021
Guidelines
published by the American Society of Hematology in 2020 recommend
annual transcranial doppler ultrasound (TCD) screening to help identify
silent cerebral infarcts in children with severe forms of sickle cell
disease (SCD). In children with abnormal TCD screenings, the guidelines
recommend transfusions every 3-4 weeks for at least a year to reduce the
risk of further silent strokes. [Read More]
|
|
Outpatient COVID-19 Convalescent Plasma Reduces Hospitalizations |
 December 21, 2021
While
more than 500,000 units of COVID-19 convalescent plasma (CCP) have been
transfused in the United States alone, the use and efficacy has become
controversial. The World Health Organization recently issued a
recommendation that CCP should not be used outside of clinical trials.
Almost all of the available randomized clinical trial data, however, are
among individuals who were hospitalized. [Read More]
|
No comments:
Post a Comment